---
title: "Akari Therapeutics delays 2024 annual report over merger accounting"
url: "https://aibio.space/news/akari-therapeutics-delays-2024-annual-report-merger-accounting/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-31"
section: "Distress"
tickers: "NASDAQ:AKTX"
source: "https://www.sec.gov/Archives/edgar/data/1541157/000095017025047872/nt_10k_december_31_2024.htm"
summary: "The company is still finishing the accounting for its November 14, 2024 business combination. It expects to file within the 15-day extension."
---

By the aibio.space news desk.

Sources

- [Akari Therapeutics Plc NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1541157/000095017025047872/nt_10k_december_31_2024.htm)

[AKTX](https://aibio.space/companies/akari-therapeutics/)

2025-03-31

# Akari Therapeutics delays 2024 annual report over merger accounting

Tickers [AKTX](https://aibio.space/companies/akari-therapeutics/)

The company is still finishing the accounting for its November 14, 2024 business combination. It expects to file within the 15-day extension.

## Key facts

- **Company**: Akari Therapeutics Plc (NASDAQ: AKTX)

- **News type**: Distress

- **Primary source**: [Akari Therapeutics Plc NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1541157/000095017025047872/nt_10k_december_31_2024.htm)

*A columned courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Akari Therapeutics, plc (Nasdaq: [AKTX](https://aibio.space/companies/akari-therapeutics/)) said it will be unable to file its Annual Report on Form 10-K for the year ended December 31, 2024 on time without unreasonable effort or expense.

The company said it needs more time to finish its financial statement close. The main reason is that accounting for the business combination that occurred on November 14, 2024 is not yet complete, along with other accounting items. Akari expects to file the report within the fifteen calendar day extension provided by Rule 12b-25, the SEC rule that gives companies a short grace period for late reports.

Akari also said it expects the annual results to differ from the prior year. The 2024 financial statements will include the results of Peak Bio, Inc. from the acquisition date of November 14, 2024. They will also show "a significant increase in operating expenses and net loss" due to merger-related and restructuring expenses, according to the company's [late-filing notice](https://www.sec.gov/Archives/edgar/data/1541157/000095017025047872/nt_10k_december_31_2024.htm).

The company listed other changes in the business, including hiring of key personnel, pipeline prioritization and changes to its available liquidity and capital resources.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

AKTX

Akari Therapeutics Plc

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/akari-therapeutics-delays-2024-annual-report-merger-accounting/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Akari Therapeutics delays 2024 annual report over merger accounting", 2025-03-31, https://aibio.space/news/akari-therapeutics-delays-2024-annual-report-merger-accounting/